I really don't understand why people would keep taking CLA when we've pointed out that it's not good.
http://groups-beta.g...bf8fd27d504586aIan Goddard May 14 2003, 12:07 pm
IAN: Thanks Tom for the additional info. Seems we
all agree that the reported CLA-induced increase of
C-reactive protein, lipid peroxidation, and insulin
resistance are logical grounds for discontinuation.Conjugated linoleic acid induces lipid peroxidation in
humans."
Conjugated linoleic acid induces lipid peroxidation in humans.
Basu S, Smedman A, Vessby B.
Section of Geriatrics/Clinical Nutrition Research, Faculty of Medicine, Uppsala University, Box 609, SE-751 25, Uppsala, Sweden. samar@basu@geriatrik.uu.se
Conjugated linoleic acid (CLA) is shown to have chemoprotective properties in various experimental cancer models. CLA is easily oxidised and it has been suggested that an increased lipid oxidation may contribute to the antitumorigenic effects. This report investigates the urinary levels of 8-iso-PGF(2alpha), a major isoprostane and 15-keto-dihydro-PGF(2alpha), a major metabolite of PGF(2alpha), as indicators of non-enzymatic and enzymatic lipid peroxidation after dietary supplementation of CLA in healthy human subjects for 3 months. A significant increase of both 8-iso-PGF(2alpha) and 15-keto-dihydro-PGF(2alpha) in urine was observed after 3 months of daily CLA intake (4.2 g/day) as compared to the control group (P<0.0001). Conjugated linoleic acid had no effect on the serum alpha-tocopherol levels. However, gamma-tocopherol levels in the serum increased significantly (P=0. 015) in the CLA-treated group. Thus, CLA may induce both non-enzymatic and enzymatic lipid peroxidation in vivo. Further studies of the mechanism behind, and the possible consequences of, the increased lipid peroxidation after CLA supplementation are urgently needed.
Publication Types:
* Clinical Trial
* Randomized Controlled Trial
PMID: 10683436 [PubMed - indexed for MEDLINE]
Clin Sci (Lond). 2000 Dec;99(6):511-6. Related Articles, Links
Click here to read
Conjugated linoleic acid induces lipid peroxidation in men with abdominal obesity.
Basu S, Riserus U, Turpeinen A, Vessby B.
Sections of Geriatrics and Clinical Nutrition Research, Faculty of Medicine, Uppsala University, Box 609, SE-751 25 Uppsala, Sweden. samar.basu@geriatrik.uu.se
Conjugated linoleic acid (CLA) has been shown in experimental studies to have chemoprotective properties, and may decrease the deposition of body fat. CLA is prone to oxidation, and it has been suggested that increased lipid oxidation may contribute to the anti-tumorigenic effects of this agent. The present study investigates the urinary levels of 8-iso-prostaglandin F(2alpha) (8-iso-PGF(2alpha)), a major isoprostane, and of 15-oxo-dihydro-PGF(2alpha), a major metabolite of PGF(2alpha), as indicators of non-enzymic and enzymic arachidonic acid oxidation respectively after dietary supplementation with CLA in middle-aged men (mean age 53 years) with abdominal obesity for 1 month in a randomized controlled trial. Significant increases in the levels of both 8-iso-PGF(2alpha) and 15-oxo-dihydro-PGF(2alpha) in urine (P<0. 0001 and P=0.0013 respectively) were observed after 1 month of daily CLA intake (4.2 g/day) as compared with the control group. The lipid peroxidation parameters had returned to their basal levels at 2 weeks after the cessation of CLA intake, and remained at the same levels for a further 2 weeks until the end of the study. CLA had no effect on serum alpha-tocopherol and gamma-tocopherol levels, or on the urinary levels of 2,3-dinor-thromboxane B(2). Thus CLA may induce both non-enzymic and enzymic lipid peroxidation in vivo in middle-aged men with abdominal obesity, without any side effects. The consequences of the increased lipid peroxidation after CLA supplementation are unknown.
Publication Types:
* Clinical Trial
* Randomized Controlled Trial
PMID: 11099394 [PubMed - indexed for MEDLINE]
http://groups-beta.g...1bad57da11044a6Diabetes Care 2002 Sep;25(9):1516-21 Treatment with dietary
trans10cis12 conjugated linoleic acid causes isomer-specific insulin
resistance in obese men with the metabolic syndrome. Riserus U, Arner
P, Brismar K, Vessby B. Department of Public Health and Caring
Sciences/Geriatrics, Uppsala University, Uppsala, Sweden.
ulf.rise...@pubcare.uu.se OBJECTIVE: Conjugated linoleic acid (CLA) is
a group of dietary fatty acids with antiobesity and antidiabetic
effects in some animals. The trans10cis12 (t10c12) CLA isomer seems to
cause these effects, including improved insulin sensitivity. Whether
such isomer-specific effects occur in humans is unknown. The aim of
this study was to investigate whether t10c12 CLA or a commercial CLA
mixture could improve insulin sensitivity, lipid metabolism, or body
composition in obese men with signs of the metabolic syndrome.
RESEARCH DESIGN AND METHODS: In a randomized, double-blind controlled
trial, abdominally obese men (n = 60) were treated with 3.4 g/day CLA
(isomer mixture), purified t10c12 CLA, or placebo.
Euglycemic-hyperinsulinemic clamp, serum hormones, lipids, and
anthropometry were assessed before and after 12 weeks of treatment.
RESULTS: Baseline metabolic status was similar between groups.
Unexpectedly, t10c12 CLA increased insulin resistance (19%; P < 0.01)
and glycemia (4%; P < 0.001) and reduced HDL cholesterol (-4%; P <
0.01) compared with placebo, whereas body fat, sagittal abdominal
diameter, and weight decreased versus baseline, but the difference was
not significantly different from placebo. The CLA mixture did not
change glucose metabolism, body composition, or weight compared with
placebo but lowered HDL cholesterol (-2%; P < 0.05). CONCLUSIONS:
These results reveal important isomer-specific metabolic actions of
CLA in abdominally obese humans. A CLA-induced insulin resistance has
previously been described only in lipodystrophic mice. Considering the
use of CLA-supplements among obese individuals, it is important to
clarify the clinical consequences of these results, but they also
provide physiological insights into the role of specific dietary fatty
acids as modulators of insulin resistance in humans. PMID: 12196420
http://groups-beta.g...bf8fd27d504586ahttp://groups-beta.g...bf8fd27d504586a